Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 11, 2010, Pages 2394-2403

  Ken Dror, G ^a   Drenos, F ^a   Humphries, S E ^a   Talmud, P J ^a   Hingorani, A D ^b   Kivima Aki M ^b   Kumari, M ^b   Bauer, K A ^c   Morrissey, J H ^d   Ireland, H A ^a,e  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e NORTHWICK PARK INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

F7 gene; Factor VII; Haplotypes; Incident coronary heart disease; Tagging SNPs

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7C; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE REPLICATION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HAPLOTYPE MAP; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MORBIDITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

ALLELES; BLOOD COAGULATION; COHORT STUDIES; CORONARY DISEASE; FACTOR VII; GENOTYPE; GREAT BRITAIN; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 78149276655     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04035.x     Document Type: Article

References (52)

1. Rao LV, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-91.
2. Bauer KA, Kass BL, Ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-6.
3. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
4. Bozzini C, Girelli D, Bernardi F, Ferraresi P, Olivieri O, Pinotti M, Martinelli N, Manzato F, Friso S, Villa G, Pizzolo F, Beltrame F, Corrocher R. Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis. Thromb Haemost 2004; 92: 541-9.
5. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
6. Junker R, Heinrich J, Schulte H, Van De Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-44.
7. Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1995; 15: 1269-79.
8. Ghaddar HM, Folsom AR, Aleksic N, Hearne LB, Chambless LE, Morrissey JH, Wu KK. Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation 1998; 98: 2815-21.
9. Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, Meade TW. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992; 68: 261-3.
10. Humphries SE, Lane A, Green FR, Cooper J, Miller GJ. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb 1994; 14: 193-8.
11. Simpson HC, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; 1: 786-90.
12. Feng D, Tofler GH, Larson MG, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Johnstone MT, Muller JE, D'Agostino RB, Levy D, Lindpaintner K. Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2000; 20: 593-600.
13. Mariani G, Bernardi F, Bertina R, Vicente VV, Prydz H, Samama M, Sandset PM, Di Nucci GD, Testa MG, Bendz B, Chiarotti F, Ciarla MV, Strom R. Serum phospholipids are the main environmental determinants of activated factor VII in the most common FVII genotype. European Union Concerted Action "Clotart". Haematologica 1999; 84: 620-6.
14. De Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet 2001; 357: 101-5.
15. Dubrey SW, Reaveley DR, Seed M, Lane DA, Ireland H, O'Donnell M, O'Connor B, Noble MI, Leslie RD. Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes 1994; 43: 831-5.
16. O'Hara PJ, Grant FJ, Haldeman BA, Gray CL, Insley MY, Hagen FS, Murray MJ. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc Natl Acad Sci USA 1987; 84: 5158-62.
17. Kudaravalli R, Tidd T, Pinotti M, Ratti A, Santacroce R, Margaglione M, Dallapiccola B, Bernardi F, Fortina P, Devoto M, Pollak ES. Polymorphic changes in the 5′flanking region of factor VII have a combined effect on promoter strength. Thromb Haemost 2002; 88: 763-7.
18. Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, Evans A, Luc G, Cambou JP, Arveiler D, Cambien F. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119: 119-27.
19. Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol 1997; 17: 2825-9.
20. Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, Manzato F, Mazzucco A, Bernardi F, Corrocher R. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000; 343: 774-80.
21. Pollak ES, Hung HL, Godin W, Overton GC, High KA. Functional characterization of the human factor VII 5′-flanking region. J Biol Chem 1996; 271: 1738-47.
22. Iacoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Benedetta Donati M. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
23. Nederhand RJ, De Maat MP, Jukema JW. Factor VII polymorphisms and myocardial infarction: what is special in Italians? REGRESS study group. Regression Growth Evaluation Statin Study. Thromb Haemost 2001; 85: 746-7.
24. Doggen CJ, Manger Cats V, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998; 80: 281-5.
25. Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrario M, Corral J, Margaglione M. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.
26. Shanker J, Perumal G, Maitra A, Rao VS, Natesha BK, John S, Hebbagodi S, Kakkar VV. Genotype-phenotype relationship of F7 R353Q polymorphism and plasma factor VII coagulant activity in Asian Indian families predisposed to coronary artery disease. J Genet 2009; 88: 291-7.
27. Carew JA, Basso F, Miller GJ, Hawe E, Jackson AA, Humphries SE, Bauer KA. A functional haplotype in the 5′ flanking region of the factor VII gene is associated with an increased risk of coronary heart disease. J Thromb Haemost 2003; 1: 2179-85.
28. Sabater-Lleal M, Martinez-Marchan E, Martinez-Sanchez E, Coll M, Vallve C, Mateo J, Souto JC, Fontcuberta J, Soria JM. Complexity of the genetic contribution to factor VII deficiency in two Spanish families: clinical and biological implications. Haematologica 2003; 88: 906-13.
29. Reiner AP, Carlson CS, Rieder MJ, Siscovick DS, Liu K, Chandler WL, Green D, Schwartz SM, Nickerson DA. Coagulation factor VII gene haplotypes, obesity-related traits, and cardiovascular risk in young women. J Thromb Haemost 2007; 5: 42-9.
30. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-22.
31. Miller GJ, Stirling Y, Esnouf MP, Heinrich J, Van De Loo J, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bioassay to activated factor VII: an international study. Thromb Haemost 1994; 71: 38-48.
32. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
33. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. Blood 1982; 59: 1086-97.
34. World Health Organization. Regional Office for Europe. Myocardial infarction community registers results of a WHO international collaborative study coordinated by the Regional Office for Europe. Copenhagen: Regional Office for Europe, World Health Organization, 1976.
35. Prineas RJ, Crow RS, Blackburn HW. The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. Boston, MA: J. Wright, 1982.
36. Marmot M, Brunner E. Cohort Profile: the Whitehall II study. Int J Epidemiol 2005; 34: 251-6.
37. Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P et al. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Genet 2009; 85: 628-42.
38. Brozovic M, Stirling Y, Harricks C, North WR, Meade TW. Factor VII in an industrial population. Br J Haematol 1974; 28: 381-91.
39. De Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005; 37: 1217-23.
40. Drenos F, Talmud PJ, Casas JP, Smeeth L, Palmen J, Humphries SE, Hingorani AD. Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Hum Mol Genet 2009; 18: 2305-16.
41. Thomas A, Lamlum H, Humphries S, Green F. Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G/A-455 (HaeIII), C/T-148 (HindIII/AluI), T/G + 1689 (AvaII), and BclI (beta-fibrinogen) and TaqI (alpha-fibrinogen), and their detection by PCR. Hum Mutat 1994; 3: 79-81.
42. Baumann RE, Henschen AH. Linkage disequilibrium relationships among four polymorphisms within the human fibrinogen gene cluster. Hum Genet 1994; 94: 165-70.
43. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, Galver L, Barrett JC, Grant SF, Farlow DN, Chandrupatla HR, Hansen M, Ajmal S, Papanicolaou GJ, Guo Y, Li M, Derohannessian S, De Bakker PI, Bailey SD, Montpetit A et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS ONE 2008; 3: e3583.
44. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-89.
45. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005; 76: 449-62.
46. Graham RR, Langefeld CD, Gaffney PM, Ortmann WA, Selby SA, Baechler EC, Shark KB, Ockenden TC, Rohlf KE, Moser KL, Brown WM, Gabriel SE, Messner RP, King RA, Horak P, Elder JT, Stuart PE, Rich SS, Behrens TW. Genetic linkage and transmission disequilibrium of marker haplotypes at chromosome 1q41 in human systemic lupus erythematosus. Arthritis Res 2001; 3: 299-305.
47. Marchini J, Cutler D, Patterson N, Stephens M, Eskin E, Halperin E, Lin S, Qin ZS, Munro HM, Abecasis GR, Donnelly P. A comparison of phasing algorithms for trios and unrelated individuals. Am J Hum Genet 2006; 78: 437-50.
48. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-6.
49. Ken-Dror G, Talmud PJ, Humphries SE, Drenos F. APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective Coronary Heart Disease Risk among UK healthy men. Mol Med 2010; 16: 389-99.
50. Miller GJ, Ireland HA, Cooper JA, Bauer KA, Morrissey JH, Humphries SE, Esnouf MP. Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost 2008; 6: 259-67.
51. Mariani G, Herrmann FH, Schulman S, Batorova A, Wulff K, Etro D, Dolce A, Auerswald G, Astermark J, Schved JF, Ingerslev J, Bernardi F. Thrombosis in inherited factor VII deficiency. J Thromb Haemost 2003; 1: 2153-8. 395 [pii].
52. Marty S, Barro C, Chatelain B, Fimbel B, Tribout B, Reynaud J, Schved JF, Giansily-Blaizot M. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia 2008; 14: 564-70.